Improving the outcomes of checkpoint inhibitors in breast cancer
Mené dans 5 pays sur 58 patientes atteintes d'un cancer HER2+ de stade avancé et résistant au trastuzumab, cet essai de phase Ib/II évalue la dose maximale tolérée, la proportion de patientes présentant une tumeur PD-L1+ répondant au traitement, et la toxicité du pembrolizumab combiné au trastuzumab, selon l'expression tumorale de PD-L1 (durées médianes de suivi : 13,6 et 12,2 mois)
Checkpoint inhibitors have revolutionised the way that cancer is treated in all developed countries, with numerous checkpoint inhibitors approved to treat multiple tumour types. Unfortunately, the results for checkpoint inhibitors in breast cancer have been less successful. Most of the positive results to date in this setting have been reported in triple-negative breast cancer, which comprises only 15% of breast cancers, but is known to induce a higher level of endogenous immune response than other breast cancer subtypes. Of substantial interest, the recently reported IMPASSION-130 study showed improvements in progression-free survival in patients with metastatic triple-negative breast cancer treated with atezolizumab (a programmed cell death 1 ligand 1 [PD-L1] inhibitor) plus nab-paclitaxel, compared with nab-paclitaxel alone. However, there was no difference in overall survival
The Lancet Oncology , commentaire, 2018